Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. on December 15, 2016, reporting events occurring on December 9, 2016. The Company is a Delaware corporation focused on animal health products.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on a material definitive agreement rather than periodic financial results.
Material Changes
On December 9, 2016, the Company entered into a distribution agreement with Henry Schein, Inc. Key terms include:
- Exclusive Distribution: Henry Schein Animal Health will serve as the exclusive distributor, seller, and promoter of the Company's Neonorm Foal product to all segments of the U.S. equine market.
- Responsibilities: The Company retains responsibility for all activities and costs to obtain federal, state, or local clearances required for distribution.
- Term: The agreement is effective December 9, 2016, for an initial period of one year, with automatic renewal for successive one-year terms unless terminated with 30 days' notice.
- Operational Terms: The agreement includes provisions for monthly service levels, annual sales targets, marketing, forecasting, ordering, delivery, payment terms, confidentiality, and indemnification.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard contractual obligations. The Company issued a press release on December 12, 2016, announcing the agreement, which is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the distribution agreement with Henry Schein, Inc., which is expected to be filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2016.
- Confirm the specific annual sales targets and monthly service levels defined in the agreement.
- Monitor the Company's progress in obtaining necessary federal, state, and local clearances for the Neonorm Foal product, as these costs and activities remain the Company's responsibility.
- Review the press release dated December 12, 2016 (Exhibit 99.1) for additional context on the strategic partnership.